Engineering Patient-Derived Tumoroids to Enable High-Throughput Screening for Immuno-Oncology

Explore a 30-minute webinar presented by Garrett Wong, MS, on engineering patient-derived tumoroids for high-throughput screening in immuno-oncology. Delve into the potential of cancer organoids as cost-effective and biologically relevant models for cancer immunotherapy research. Learn about a proof-of-concept immunotherapy screening platform that utilizes tumoroids to validate the cytotoxic activity of Natural Killer (NK) cells. Gain insights from Wong's expertise, developed through his academic background in modeling skeletal muscle disorders and his current role as a manager for the cell biology services team at Thermo Fisher Scientific. Discover how this innovative approach could advance the field of cancer immunotherapy and potentially lead to more effective treatments.